Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$6.53
+10.3%		$6.21
$2.74
▼
$8.44
$1.81B1.24.90 million shs8.13 million shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$41.80
-1.1%		$37.25
$10.38
▼
$43.73
$7.22B0.382.03 million shs1.04 million shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$101.07
-0.4%		$104.06
$49.67
▼
$111.86
$6.61B-0.031.52 million shs3.00 million shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$94.11
-11.0%		$110.35
$54.74
▼
$130.00
$6.45B0.52595,804 shs2.97 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+10.30%+14.50%-15.08%+24.62%+58.50%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.15%+1.06%+4.47%+20.32%+281.04%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.42%+0.07%-2.26%+8.61%+94.85%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-11.04%-16.41%-26.65%-12.18%+76.27%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$6.53
+10.3%		$6.21
$2.74
▼
$8.44
$1.81B1.24.90 million shs8.13 million shs
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
$41.80
-1.1%		$37.25
$10.38
▼
$43.73
$7.22B0.382.03 million shs1.04 million shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$101.07
-0.4%		$104.06
$49.67
▼
$111.86
$6.61B-0.031.52 million shs3.00 million shs
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$94.11
-11.0%		$110.35
$54.74
▼
$130.00
$6.45B0.52595,804 shs2.97 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
+10.30%+14.50%-15.08%+24.62%+58.50%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-1.15%+1.06%+4.47%+20.32%+281.04%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
-0.42%+0.07%-2.26%+8.61%+94.85%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-11.04%-16.41%-26.65%-12.18%+76.27%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
2.67
Moderate Buy$9.4043.95% Upside
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
2.85
Moderate Buy$45.909.81% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.36
Hold$108.116.97% Upside
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2.93
Moderate Buy$137.3345.93% Upside

Current Analyst Ratings Breakdown

Latest ABCL, COGT, MIRM, and LNTH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Robert W. Baird logo
Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$123.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$137.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOutperform$148.00 ➝ $135.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/6/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $9.00
8/6/2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$11.00 ➝ $12.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$145.00 ➝ $140.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetMarket Outperform$146.00 ➝ $137.00
8/6/2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$185.00 ➝ $140.00
8/4/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
CJS Securities logo
CJS Securities
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeMarket Outperform ➝ Market Perform
8/3/2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold$125.00 ➝ $102.50
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
$75.13M26.54N/AN/A$3.23 per share2.02
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/A$3.84 per shareN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.54B4.27$6.36 per share15.90$16.43 per share6.15
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
$521.31M11.01$0.05 per share2,075.16$6.12 per share15.38
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$146.41M-$0.48N/AN/AN/A-248.83%-17.22%-12.29%N/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/10/2026 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$233.56M$4.1524.3518.79N/A18.05%29.32%15.00%N/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$23.36M-$13.61N/A723.92N/A-139.18%-26.88%-9.06%N/A

Latest ABCL, COGT, MIRM, and LNTH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
-$0.5550N/AN/AN/A$0.00 millionN/A
8/6/2026Q2 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.30$1.55+$0.25$1.11$363.23 million$388.18 million
8/5/2026Q2 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.1443-$0.18-$0.0357-$0.18$7.85 million$4.05 million
8/5/2026Q2 2026
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
-$0.7425-$1.06-$0.3175-$1.06$166.33 million$176.24 million
5/11/2026Q1 2026
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
-$0.22-$0.14+$0.08-$0.14$5.41 million$8.32 million
5/7/2026Q1 2026
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.25$1.46+$0.21$1.80$354.48 million$377.33 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/AN/AN/AN/AN/A
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
N/A
14.05
14.05
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
0.41
15.14
15.14
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.47
2.83
2.64
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
1.28
2.09
1.99

Institutional Ownership

CompanyInstitutional Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
61.42%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
N/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
28.40%
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
6.59%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.70%
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
8.32%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
500305.38 million218.65 millionOptionable
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
80170.87 million159.61 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1,19365.11 million64.00 millionOptionable
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
14060.98 million55.91 millionOptionable

Recent News About These Companies

The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-the-manufacturers-life-insurance-company-grows-stock-holdings-in-mirum-pharmaceuticals-inc-mirm-2026-08-07/
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-inc-nasdaqmirm-receives-consensus-recommendation-of-moderate-buy-from-brokerages-2026-08-07/
Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
August 6 at 7:59 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mirum-pharmaceuticals-reports-second-quarter-200100823.html
TD Cowen Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00
August 6 at 3:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/td-cowen-cuts-mirum-pharmaceuticals-nasdaqmirm-price-target-to-14000-2026-08-06/
Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%
August 6 at 2:58 PM  |  msn.comhttps://www.msn.com/en-us/money/other/citizens-says-fda-s-unexpected-phase-3-request-clouds-mirum-s-near-term-outlook-mirm-stock-crashes-15/ar-AA29xrkM
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised
August 6 at 12:26 PM  |  zacks.comhttps://www.zacks.com/stock/news/2970138/mirum-s-q2-earnings-lag-estimates-revenues-beat-2026-view-raised?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2970138
Mirum Pharmaceuticals (NASDAQ:MIRM) Shares Gap Down Following Weak Earnings
August 6 at 10:39 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-nasdaqmirm-shares-gap-down-following-weak-earnings-2026-08-06/
Citizens Jmp Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $137.00
August 6 at 9:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/citizens-jmp-cuts-mirum-pharmaceuticals-nasdaqmirm-price-target-to-13700-2026-08-06/
HC Wainwright Cuts Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $140.00
August 6 at 8:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-cuts-mirum-pharmaceuticals-nasdaqmirm-price-target-to-14000-2026-08-06/
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Sells $193,733.60 in Stock
August 6 at 6:51 AM  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mirm-insider-buying-and-selling-2026-08-06/
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
August 5 at 12:00 AM  |  seekingalpha.comhttps://seekingalpha.com/article/4931412-mirum-pharmaceuticals-inc-mirm-q2-2026-earnings-call-transcript
Mirum Pharmaceuticals Q2 Earnings Call Highlights
August 5 at 11:02 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-q2-earnings-call-highlights-2026-08-05/
Mirum Pharmaceuticals (NASDAQ:MIRM) Announces Earnings Results, Misses Estimates By $0.32 EPS
August 5 at 8:40 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-nasdaqmirm-announces-earnings-results-misses-estimates-by-032-eps-2026-08-05/
Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics
August 5 at 7:01 PM  |  zacks.comhttps://www.zacks.com/stock/news/2969188/compared-to-estimates-mirum-pharmaceuticals-mirm-q2-earnings-a-look-at-key-metrics?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm-2969188
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates
August 5 at 6:26 PM  |  zacks.comhttps://www.zacks.com/stock/news/2969142/mirum-pharmaceuticals-inc-mirm-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969142
Mirum Pharmaceuticals (NASDAQ:MIRM) SVP Jolanda Howe Sells 1,840 Shares of Stock
August 5 at 5:21 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/mirum-pharmaceuticals-nasdaqmirm-svp-jolanda-howe-sells-1840-shares-of-stock-2026-08-05/
Arrowstreet Capital Limited Partnership Has $6.27 Million Stake in Mirum Pharmaceuticals, Inc. $MIRM
August 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-arrowstreet-capital-limited-partnership-has-627-million-stake-in-mirum-pharmaceuticals-inc-mirm-2026-08-03/
Mirum Pharmaceuticals, Inc. $MIRM Shares Bought by First Trust Advisors LP
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-mirum-pharmaceuticals-inc-mirm-shares-bought-by-first-trust-advisors-lp-2026-07-31/
Janus Henderson Group PLC Has $641.76 Million Holdings in Mirum Pharmaceuticals, Inc. $MIRM
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-has-64176-million-holdings-in-mirum-pharmaceuticals-inc-mirm-2026-07-30/
Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026
July 29, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mirum-pharmaceuticals-announce-second-quarter-200100522.html
What is HC Wainwright's Forecast for MIRM FY2028 Earnings?
July 29, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/what-is-hc-wainwrights-forecast-for-mirm-fy2028-earnings-2026-07-29/

New MarketBeat Followers Over Time

Media Sentiment Over Time

AbCellera Biologics stock logo

AbCellera Biologics NASDAQ:ABCL

$6.53 +0.61 (+10.30%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$6.64 +0.11 (+1.68%)
As of 08:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cogent Biosciences stock logo

Cogent Biosciences NASDAQ:COGT

$41.80 -0.47 (-1.11%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$42.62 +0.82 (+1.96%)
As of 08:53 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$101.07 -0.43 (-0.42%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$101.18 +0.11 (+0.10%)
As of 07:57 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Mirum Pharmaceuticals stock logo

Mirum Pharmaceuticals NASDAQ:MIRM

$94.11 -11.68 (-11.04%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$94.78 +0.67 (+0.71%)
As of 08:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas